Showing results (281-290 of 300) with videos related to

Sort By:
Pageof 30
Bone Marrow Transplantation|May 4, 2010
Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilizationH V Naina, R K Pruthi, D J Inwards, et al.
Leukemia|May 29, 2010
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosisA Tefferi, T L Lasho, O Abdel-Wahab, et al.
Leukemia|October 25, 2016
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependenceA Tefferi, H K Al-Ali, G Barosi, et al.
Blood Cancer Journal|March 9, 2013
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH SymposiumA Tefferi, O Abdel-Wahab, F Cervantes, et al.
Bone Marrow Transplantation|December 18, 2007
Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant ResearchM R Bishop, B R Logan, S Gandham, et al.
Bone Marrow Transplantation|September 5, 2017
A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myelomaA Dispenzieri, A D'Souza, M A Gertz, et al.
Leukemia|March 28, 2013
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomesM M Patnaik, E Padron, R R LaBorde, et al.
Leukemia|June 11, 2013
AKT is a therapeutic target in myeloproliferative neoplasmsI Khan, Z Huang, Q Wen, et al.
Leukemia|March 6, 2009
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosisA Tefferi, A Pardanani, K-H Lim, et al.
Blood|September 25, 1998
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantationV Ratanatharathorn, R A Nash, D Przepiorka, et al.
Pageof 30